Author

Won-Mook Choi

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Real-world outcomes of lenvatinib versus sorafenib as the second-line therapy after atezolizumab plus bevacizumab in patients with hepatocellular carcinoma: a large-scale multicenter study in Korea.

INTRODUCTION After first‑line atezolizumab plus bevacizumab (ATE + BEV) in hepatocellular carcinoma (HCC), optimal second‑line (2L) therapy remains unclear. This study compared the real‑world effectiveness and hepatotoxicity of lenvatinib versus sorafenib as 2L treatment after ATE + BEV. METHODS This retrospective, m...

Min-Ji Lee, Su-Bin Lim, J. Shim et al. · Hepatology International · 0 citations

Open access Aug 2026

Combined hepatocellular-cholangiocarcinoma shows distinct recurrence patterns and poorer postoperative outcomes compared to hepatocellular carcinoma

Combined hepatocellular–cholangiocarcinoma (cHCC-CCA) is an uncommon primary liver cancer with distinct histology but overlapping clinical features with hepatocellular carcinoma (HCC). This study compared postoperative outcomes between cHCC-CCA and HCC in patients with very-early or early-stage tumors. We re...

Yeongseok Hwang, Subin Heo, Y. Yoon et al. · International Journal of Sur... · 0 citations

Open access Sep 2026

Clinical features, treatment patterns, and outcomes of young-onset hepatocellular carcinoma: a tertiary cohort analysis with a nationwide population-based study.

Background/Aims Hepatocellular carcinoma (HCC) in younger patients is uncommon, and its clinical behavior and prognosis remain unclear. We aimed to evaluate the characteristics, treatment patterns, and outcomes of young-onset HCC using large-scale datasets. Methods This study analyzed two cohorts: the Asan Medical Ce...

Eunju Kim, Min Young Kim, Jina Park et al. · Journal of Liver Cancer · 0 citations